Improving risk stratification models for patients with MGUS and smoldering myeloma

Key features of the PANGEA model: improving risk stratification in myelomaПодробнее

Updated risk stratification model for smoldering multiple myelomaПодробнее

Prevalence of Smoldering Multiple Myeloma: Results from the iStopMM StudyПодробнее

Smoldering Myeloma: Treatment and Risk StratificationПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Risk stratification models for smoldering WM and strategies to improve theseПодробнее

Improving the risk stratification of patients with smoldering myelomaПодробнее

Genomic profiling of smoldering myeloma to improve risk stratification modelsПодробнее

The PANGEA model: improving risk stratification in multiple myelomaПодробнее

Risk stratification models for smoldering myelomaПодробнее

Better understanding smoldering myeloma & improving the outcomes of patients with high-risk myelomaПодробнее

Risk stratification of MGUSПодробнее

The PANGEA model: enhancing risk assessment for individuals with high-risk smoldering myelomaПодробнее

Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMMПодробнее

Risk Stratification for MGUS | Dr. S. Vincent Rajkumar | Oncology BrothersПодробнее

Managing patients with smoldering myeloma: the importance of risk stratificationПодробнее

Risk stratification in multiple myelomaПодробнее

Update on Risk Stratification in MGUS and SMM | Doctors Callander and Beksac | IMS 2023Подробнее

Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023Подробнее

Diagnosis and Risk Stratification of Plasma Cell Disorders (pt 1 of 5 - IMF ASH Satellite)Подробнее

Risk Stratification of Plasma Cell DisordersПодробнее